About this trial
AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC).
Patient Profile
This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body.
Where’s this trial being run?
St James’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | AcceleRET-Lung |
|---|---|
| Number: | 20-21 |
| Full Title: | A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer |
| Principal Investigator: | Dr Sinead Cuffe |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Hoffmann-La Roche |
| Recruitment Started: |
Global: 10th July 2020 Ireland: Yes |
| Global Recruitment Target: | 226 |
|---|---|
| Ireland Recruitment Target: | 3 |